Advertisement

European Journal of Clinical Pharmacology

, Volume 30, Issue 1, pp 89–92 | Cite as

Effect of cirrhosis and renal failure on the kinetics of clotiazepam

  • H. R. Ochs
  • D. J. Greenblatt
  • M. Knüchel
Originals

Summary

The kinetics of a single 5-mg oral dose of the thienodiazepine clotiazepam was evaluated in a series of patients with biopsy-proven cirrhosis, and in patients with renal insufficiency requiring maintenance hemodialysis, compared to healthy matched controls. Clotiazepam volume of distribution (Vz) was significantly smaller in cirrhotic patients than in controls (1.83 vs 2.57 l/kg), and total clearance was likewise reduced (2.15 vs 3.15 ml/min/kg). Elimination half-life was similar between groups (10.0 vs. 10.2h). There were no significant differences between renal failure and control patients in clotiazepam Vz, oral clearance, or elimination half-life. Thus cirrhosis is associated with reduced clearance of clotiazepam, probably due to impairment of its microsomal oxidation. However clotiazepam disposition is not significantly altered in dialysis-dependent renal insufficiency patients.

Key words

clotiazepam liver cirrhosis renal insufficiency pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ochs HR, Greenblatt DJ, Verburg-Ochs B, Harmatz JS, Grehl H (1984) Clotiazepam disposition: Influence of age, sex, oral contraceptives, cimetidine, isoniazid, and ethanol. Eur J Clin Pharmacol 26: 55–59Google Scholar
  2. 2.
    Arendt R, Ochs HR, Greenblatt DJ (1982) Electron-capture GLC analysis of the thienodiazepine clotiazepam. Arzneimittelforsch 32: 435–455Google Scholar
  3. 3.
    Ochs HR, Greenblatt DJ, Eckardt B, Harmatz JS, Shader RI (1983) Repeated diazepam dosing in cirrhotic patients: Cumulation and sedation. Clin Pharmacol Ther 33: 471–476Google Scholar
  4. 4.
    Branch RA, Morgan MH, James J, Read AE (1976) Intravenous administration of diazepam in patients with chronic liver disease. Gut 17: 975–983Google Scholar
  5. 5.
    Andreasen PB, Hendel J, Greisen G, Hvidberg EF (1976) Pharmacokinetics of diazepam in disordered liver function. Eur J Clin Pharmacol 10: 115–120Google Scholar
  6. 6.
    Juhl RP, Van Thiel DH, Dittert LW, Smith RB (1984) Alprazolam pharmacokinetics in alcoholic liver disease. J Clin Pharmacol 24: 113–119Google Scholar
  7. 7.
    Roberts RK, Wilkinson GR, Branch RA, Schenker S (1978) Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (Librium). Gastroenterology 75: 479–485Google Scholar
  8. 8.
    Jochemsen R, Joeres RP, Wesselman JGJ, Richter E, Breimer DD (1983) Pharmacokinetics of oral brotizolam in patients with liver cirrhosis. Br J Clin Pharmacol 16: 315s-322sGoogle Scholar
  9. 9.
    Ochs HR, Greenblatt DJ, Kaschell HJ, Klehr U, Divoll M, Abernethy DR (1981) Diazepam kinetics in patients with renal insufficiency or hyperthyroidism. Brit J Clin Pharmacol 12: 829–832Google Scholar
  10. 10.
    Greenblatt DJ, Murray TG, Audet PR, Locniskar A, Koepke HH, Walker BR (1983) Multiple-dose kinetics and dialyzability of oxazepam in renal insufficiency. Nephron 34: 234–238Google Scholar
  11. 11.
    Ochs HR, Greenblatt DJ, Klehr U (1984) Disposition of oxazepam in patients on maintenance hemodialysis. Klin Wochenschr 62: 765–767Google Scholar
  12. 12.
    Ochs HR, Rauh HW, Greenblatt DJ, Kaschell JH (1984) Clorazepate dipotassium and diazepam in renal insufficiency: Serum concentrations and protein binding of diazepam and desmethyldiazepam. Nephron 37: 100–104Google Scholar
  13. 13.
    Vinik HR, Reves JG, Greenblatt DJ, Abernethy DR, Smith LR (1983) The pharmacokinetics of midazolam in chronic renal failure patients. Anesthesiology 59: 390–394Google Scholar
  14. 14.
    Kampf D, Hümpel M, Lerche U, Kessel M (1981) Effects of uremia and hemodialysis on lormetazepam disposition. Clin Pharmacol Ther 30: 77–85Google Scholar
  15. 15.
    Murray TG, Chiang ST, Koepke HH, Walker BR (1981) Renal disease, age, and oxazepam kinetics. Clin Pharmacol Ther 30: 805–809Google Scholar
  16. 16.
    Busch U, Molzahn M, Bozler G, Koss FW (1981) Pharmacokinetics of oxazepam following multiple administration in volunteers and patients with chronic renal disease. Arzneimittelforsch 31: 1507–1511Google Scholar
  17. 17.
    Abel JG, Sellers EM, Naranjo CA, Shaw J, Kadar D, Romach MK (1979) Inter- and intrasubject variation in diazepam free fraction. Clin Pharmacol Ther 26: 247–255Google Scholar
  18. 18.
    Grossman SH, Davis D, Kitchell BB, Shand DG, Routledge PA (1982) Diazepam and lidocaine plasma protein binding in renal disease. Clin Pharmacol Ther 31: 350–357Google Scholar
  19. 19.
    Greenblatt DJ, Sellers EM, Koch-Weser J (1982) Importance of protein binding for the interpretation of serum or plasma drug concentrations. J Clin Pharmacol 22: 259–263Google Scholar
  20. 20.
    Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18: 377–390Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • H. R. Ochs
    • 1
    • 2
    • 3
  • D. J. Greenblatt
    • 1
    • 2
  • M. Knüchel
    • 1
    • 2
  1. 1.Medizinische UniversitätsklinikUniversity of BonnFederal Republic of Germany
  2. 2.Division of Clinical Pharmacology, Departments of Psychiatry and MedicineTufts-New England Medical CenterBostonUSA
  3. 3.MarienkrankenhausSoestFederal Republic of Germany

Personalised recommendations